BRIEF—Catalent to buy B-MS' Italian site

US pharma major Bristol-Myers Squibb (B-MS) will maintain a presence in Italy through its medicines alone after agreeing to sell its Anagni manufacturing facility to Catalent.

The oral solid, biologics, and sterile product manufacturing and packaging facility has served as one of the primary launch facilities for new medicines from B-MS to treat serious diseases such as cancer and cardiovascular disease.

Upon closing, Catalent will continue to manufacture B-MS' current product portfolio at the site.